Novo Nordisk today announced a decision to focus all its research and development (R&D) resources on the company's growing pipeline of protein-based pharmaceuticals. As a result of this decision the company's R&D activities within small molecules for oral treatment of diabetes will be discontinued and existing projects divested.
Novo Nordisk, focuses R&D on therapeutic proteins - discontinues R&D within small molecules
| Source: Novo Nordisk A/S
Attachments
